articleTop 10% cited
Protective effects of nebivolol against anthracycline-induced cardiomyopathy: A randomized control study
International Journal of Cardiology · 2012 · Vol. 167(5) · pp. 2306–2310
Mehmet Güngör Kaya✉(Erciyes University)Metin Özkan(Erciyes University)Özgür Günebakmaz(Erciyes University)Hasan Akkaya(Erciyes University)Esma Kaya(Erciyes University)Mahmut Akpek(Erciyes University)Nihat Kalay(Erciyes University)Mustafa Dikilitaş(Erciyes University)Mikail Yarlıoğlueş(Erciyes University)Halıt Karaca(Erciyes University)Velı Berk(Erciyes University)İdris Ardıç(Erciyes University)Ali Ergin(Erciyes University)Yat Yin Lam(Chinese University of Hong Kong)
Chemotherapy-induced cardiotoxicity and mitigationElectron Spin Resonance StudiesCancer Treatment and PharmacologyMedicineNebivololCardiotoxicityPlaceboEjection fractionInternal medicineCardiologyBreast cancerCardiomyopathyChemotherapy
MeSH terms
NebivololAdultAntineoplastic AgentsBenzopyransCardiotonic AgentsDouble-Blind MethodEthanolaminesFemaleHumansMiddle AgedCardiomyopathiesProspective StudiesUltrasonographyAnthracyclines
Citations
321
FWCI
11.39
field-weighted impact
References
43
Percentile
99%
vs. same field & year
Citations per year
Cited by
Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention
Heart · 2017 · 518 citations
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
European Heart Journal · 2016 · 2,487 citations
References
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial
The Lancet · 1999 · 4,886 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.